Entity > Corporation > US > New York City New York > Synlogic

About Synlogic

Synlogic is a clinical-stage biotechnology company developing drugs for metabolic and immunological diseases using its proprietary synthetic technology approach.

Synlogic Targets Areas of Unmet Medical Needs: Synlogic specifically targets four areas of unmet medical need: rare metabolic diseases, enteric hyperoxaluria, gout, and immunological and inflammatory diseases The company's lead programs target patients with rare genetic metabolic diseases such as phenylketonuria and secondary hyperoxaluria.

Collaborations and Partnerships: Synlogic is also collaborating with Roche in a research collaboration focused on the discovery of a novel synthetic biologic for the treatment of inflammatory bowel disease, and with Ginkgo Bioworks to include additional unpublished preclinical assets, combining Synlogic's approach to synthetic biotics with Ginkgo's codebase and foundry services.

Founded in 2014 by Synthetic Biology Experts: Synlogic was founded in 2014 by two of the world's leading synthetic biology experts, James Collins, PhD, and Tim Lu, MD, PhD, of the Massachusetts Institute of Technology. The company is made up of visionary scientists - pioneering biologists and genetic engineers working to transform drug discovery and disease treatment in a new way. Synlogic combines synthetic biology, a form of precision biological engineering, with the principles of traditional drug discovery to develop medicines for diseases that require new approaches.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Synlogic

Company Attribute Value
Name Synlogic
Url synlogictx
Wikipedia wikipedia
Google google
Wikidata wikidata



New York City, US
4 Jul 2024

New York City, US
4 Jul 2024


Page: 1 Desktop | Laptop Devices
Synlogic Therapeutics: Home
Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease.
Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of ... › biotech › end-line-synl...
Layoffs, end of line for Synlogic after PKU drug's phase 3 fail
Feb 9, 2024 — As a result, the company will cease operations and lay off more than 90% of its workforce this month. The remaining employees will be involved ... › quote › SYBX
Synlogic, Inc. (SYBX) Stock Price, News, Quote & History
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the ... › news › synlogic-announces...
Synlogic Announces Decision to Discontinue Synpheny-3 ...
Feb 8, 2024 — The decision was not based on concerns regarding safety or tolerability. Synlogic will now work with the Synpheny-3 clinical trial sites ... › Market Activity › Stocks
Synlogic, Inc. Common Stock (SYBX)
Discover real-time Synlogic, Inc. Common Stock (SYBX) stock prices, quotes, historical data, news, and Insights for informed trading and investment ... › ... › advertisement feature
Synlogic probiotics turn up the heat on cancer and ...
Synlogic is manufacturing synthetic biotic medicines engineered to deliver multimodal therapeutic activities locally.
Related Searches
Related Searches
Synlogic PKU
Synlogic linkedin
Synlogic news
Google My Business
Google My Business

Synlogic (Biotechnology company in Cambridge, Massachusetts)

  • Address : 301 Binney St #402, Cambridge, MA 02142
  • Phone : (617) 401-9975

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 193744